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Glioblastoma is the most malignant cancer in the brain and currently
incurable. It is urgent to identify effective targets for this lethal disease.
Inhibition of such targets should suppress the growth of cancer cells and,
ideally also precancerous cells for early prevention, but minimally affect their
normal counterparts. Using genetic mouse models with neural stem cells
(NSCs) or oligodendrocyte precursor cells (OPCs) as the
cells-of-origin/mutation, it is shown that the susceptibility of cells within the
development hierarchy of glioma to the knockout of insulin-like growth factor
I receptor (IGF1R) is determined not only by their oncogenic states, but also
by their cell identities/states. Knockout of IGF1R selectively disrupts the
growth of mutant and transformed, but not normal OPCs, or NSCs. The
desirable outcome of IGF1R knockout on cell growth requires the mutant cells
to commit to the OPC identity regardless of its development hierarchical
status. At the molecular level, oncogenic mutations reprogram the cellular
network of OPCs and force them to depend more on IGF1R for their growth. A
new-generation brain-penetrable, orally available IGF1R inhibitor harnessing
tumor OPCs in the brain is also developed. The findings reveal the cellular
window of IGF1R targeting and establish IGF1R as an effective target for the
prevention and treatment of glioblastoma.
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1. Introduction
Adult gliomas are the most common can-
cers of the central nervous system (CNS).[1]
Despite many years of efforts, the progno-
sis of malignant gliomas, particularly the
most advanced one, glioblastoma multi-
forme (GBM), remains dismal. Therefore,
it is urgent to identify effective targets for
this lethal disease. Inactivation of a promis-
ing druggable target should suppress the
growth of cancer cells and, ideally also pre-
transforming cells for the purpose of pre-
vention, but minimally affects normal cells.
The cell-of-origin can be considered as a
rational “normal” reference, as it shares sig-
nificantly more key features with pretrans-
forming and cancer cells than with irrele-
vant cell types.
Following this concept, two studies iden-
tified Bone marrow X-linked kinase (BMX)
selectively suppressed the self-renewal of
human glioma tumor initiating cells (TICs)
but not affected either cultured neural
stem cells (NSCs) or astrocytes,[2,3] both of
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which have been considered as the putative cells-of-origin for hu-
man GBMs. The specificity of glioma TICs to BMX targeting is
likely due to the absence of BMX in normal brain cells.[2,3] BMX
may represent a unique case as many more genes should be
shared by both cancer cells and their cells-of-origin. Indeed, by
using a genetic mouse glioma model with NSCs as the putative
cell-of-origin,[4] Shi et al. identified Gboxin, an inhibitor targeting
mitochondrial F0F1 ATP synthase,
[5] selectively suppressed pri-
mary mouse and human glioblastoma cells but not that of mouse
embryonic fibroblasts (MEFs) or astrocytes. However, when us-
ing the NSCs as reference, Gboxin exhibited certain toxicity, al-
though not as prominent as glioma TICs. Moreover, in both stud-
ies, it is unknown whether the identified genes function as spe-
cific targets to suppress spontaneous gliomagenesis in an in vivo
context.
Oligodendrocyte precursor cells (OPCs) are a major type of
glial cells in the brain, and, similar to NSCs, can self-renew
throughout their life.[6] Using genetic mouse models combined
with lineage tracing techniques, many laboratories including
ours showed that OPCs may function as the putative cell-of-
origin, not only for GBM,[4,7–10] but also for lower-grade adult
gliomas[11,12] and pediatric gliomas,[13] highlighting that OPC-
originated malignancies represent an important pathologic entity
in human gliomas. Thus, OPC-originating genetic glioma mod-
els serve as a useful experimental model system to identify and
validate therapeutic targets for glioma treatment and early inter-
vention.
Insulin-like growth factor (IGF) signaling has been associ-
ated with the pathogenesis of many human cancers, includ-
ing gliomas.[14] The increased expression of insulin-like growth
factor I receptor (IGF1R) and/or IGFs has been reported in
glioma tissues and cerebrospinal fluid from GBM patients.[15–18]
Interference with IGF1R function was shown to inhibit the
growth of glioma cell lines in vitro and in preclinical mouse
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models.[15,16,19–22] However, it remains unclear whether all cells
in the development hierarchy of glioma respond to IGF1R tar-
geting equally, considering the highly heterogeneous features
of GBMs in a native tumor. It is an important topic given that
the therapies targeting IGF1R have been undergoing in clinical
trials.[23] In addition, it is unknown theoretically whether target-
ing IGF1R could sufficiently suppress the initiation and progres-
sion of glioma in the native in vivo context, and whether it is spe-
cific to tumor cells given the presumption that IGF1R is widely
expressed in many cells including normal NSCs and OPCs. In
this study, we addressed these important questions by using ge-
netic autochthonous mouse glioma models, in combination with
ex vivo cell culture system as well as patient-derived xenografts
(PDX) models.
2. Results
2.1. Single-Cell Transcriptomics Reveals a Lineage Development
Hierarchy in Adult OPC-Derived Gliomas
In order to delineate the intratumoral hierarchy of OPC-
originated gliomas, we resorted to a genetic mouse model
(referred to as CKO_NG2-CreER, Figure 1A) and performed
droplet-based single-cell RNA sequencing (scRNA-seq).[8] In the
CKO_NG2-CreER model, tumor suppressors Trp53 and NF1 were
specifically inactivated in adult OPCs using a temporally con-
trollable OPC-specific NG2-CreER transgene. In addition, a Cre-
recombinase-dependent lineage-tracing reporter tdTomato was
incorporated to visualize all initially generated mutant cells and
their progeny (including tumors developed at the later stage, as
shown in Figure 1B). In agreement with previous reports,[4,8] we
confirmed that in this model the NG2-CreER transgene solely la-
beled OPCs and nonneural lineage pericytes, but not other neu-
roglia, or neural stem cells (NSCs) residing in all brain germi-
nal zones examined (including the subventricular zones from
the lateral, third, and fourth ventricles as wells as the hippocam-
pus, data not shown). Therefore, the CKO_NG2-CreER model rep-
resents an in vivo experimental system to study the biology of
gliomas with OPCs as the cell-of-origin.
scRNA-seq for the cells dissociated from a CKO_NG2-CreER tu-
mor (Figure 1B) identified 12 distinct clusters, visualized using
t-distributed stochastic neighbor embedding (t-SNE, Figure 1C).
Referring to known cellular markers in the brain,[24] we could
identify the cell identities/states of ten clusters (Figure 1D; Fig-
ure S1, Supporting Information), including two for OPCs (C5
and C7), two for microglia (C1 and C4), one each for astrocytes
(C2), endothelial cells (C3), oligodendrocytes (C6), pericytes (C9),
neurons (C11), and T/dendritic cells (C12). Projection of lineage
marker tdTomato onto the t-SNE map further revealed that 4 clus-
ters (C2, C6, C7, and C9) were likely derived from NG2-CreER
labeled cells and/or their progeny (Figure 1E). As expected, all
hematopoietic lineage clusters were devoid of tdTomato expres-
sion, concordant to the current view that they are unrelated to the
OPC or pericyte lineage. One interesting observation is that some
endothelial cells in C3 exhibited detectable tdTomato signals (Fig-
ure 1E). Although it is surely possible that OPC-derived glioma
cells may transdifferentiate into endothelial cells, we could not ex-
clude that the signals came from the contamination of the debris
of pericytes or astrocytes, both of which tightly associated with
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Figure 1. Single-cell transcriptomics and the grafting assay reveal the TIC function of tumor OPCs in adult OPC-derived gliomas. A) The genetic config-
uration of the CKO_NG2-CreER mouse model. B) The gross image of a tumor brain used for the scRNA-seq in (C). C) The tSNE map of all sequenced
cells from the tumor in (B). The cluster containing tumor OPCs is circled. D) The Violin plots of some marker genes from the clusters defined in (C).
Same color code is used in (C) and (D). E–H) Projection of the lineage or marker genes as indicated onto the tSNE map in (C). The cluster containing
tumor OPCs is circled. I) The pseudo-time plot of all tdTomato+ cells from Clusters 2, 5, 6, and 7. The presumed differentiation directions are marked
as dotted arrow lines. J) The tSNE map of a mouse CKO_NG2-CreER glioma cell line from the scRNA-seq data. Distinct clustered are marked by different
colors. K) Projection of the marker genes as indicated onto the tSNE map in (J). L) The representative FACS plot showing the expression of PDGFR𝛼 on
mouse tumor OPCs. M) The Western blots validate the expression of FACS-sorted glioma cells based on their surface PDGFR𝛼 expression. N) The in
vitro sphere assay of tumor OPCs based on their surface PDGFR𝛼 expression sorted by FACS. Scale bar: 100 µm. O) The survival curves of mice grafted
with PDGFR𝛼 high/low tumor OPC fractions, N = 4 mice for each group, **p < 0.01.
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endothelial cells in vivo. Future study is warranted to distinguish
these possibilities.
In the previous work, we and others have identified a sub-
population of tumor cells in OPC-derived glioma models by
both bulk RNA sequencing and in situ immunofluorescence
staining.[4,7,8,25] We could here assign this subpopulation to the
cluster 7 on the t-SNE map of the scRNA-seq dataset based on
their coexpression of both tdTomato and OPC makers including
PDGFR𝛼 and CSPG4 (NG2) (Figure 1D–G; Figure S1, Support-
ing Information). This cluster also enriched some well-known
stemness markers such as Sox11, Sox4, Nestin, Ptprs, and Cdk4
(Figure 1H; Figure S1, Supporting Information), suggesting that
they may function as the TICs in the tumor.
In the brain of the wild-type (WT) or CKO model at the pre-
transforming stage, we could readily see tdTomato-labeled OPCs
and oligodendrocytes, but not astrocytes (data not show), con-
sistent with the notion that OPCs can further develop along the
oligodendrocyte lineage but not be able to transdifferentiate into
astrocytes. Nevertheless, we detected the clusters of tumor cells
exhibiting prominent features of oligodendrocytes and astrocytes
(C6 and C2, respectively) that were also labeled by tdTomato
(Figure 1E). Therefore, scRNA-seq not only suggests that tumor
OPCs, resembling their normal counterparts, can further differ-
entiate into the oligodendrocyte state (C6), but also possesses
the capacity to transdifferentiate into astrocyte-like cells (C2). In-
terestingly, in parallel to C7, we also identified a second cluster
(C5) that exhibited prominent OPC feature. Given that they were
largely devoid of tdTomato, we reasoned that they represented
normal OPCs in the tumor. Supporting this notion, this cluster of
cells expressed less stemness markers compared to those in C7
(Figure 1D–H). Interestingly, C5 also harbored a small fraction
of tdTomato+ cells, implicating that tumor OPCs could partially
“differentiate” into more “normal” OPC-like status (Figure 1E).
To further confirm the lineage relationship among tdTomato
labeled neuroepithelium-derived cells, we performed pseudo-
time analysis of all tdTomato+ cells from these four clusters (C2,
C5, C6, and C7). The pseudo-time plot in Figure 1I revealed that
tumor OPCs, tumor oligo- and tumor astrocyte-like cells occu-
pied the three ends of the lineage trajectory, and there was evident
continuity between tumor OPC and astrocyte-like cells. Intrigu-
ingly, tumor-OPCs appeared to undergo a more “normal” OPC-
like state before further differentiating into mature astrocyte- or
oligodendrocyte-like states. Therefore, scRNA-seq suggests the
existence of a development hierarchy in OPC-derived mouse
gliomas; and tumor cells representing stem cells/progenitors, as-
trocytes, OPCs, and oligodendrocytes coexist within this hierar-
chy, nicely concordant with a recent comprehensive scRNA-seq
analysis of human GBM.[26]
2.2. Tumor OPCs Function as TICs in Adult OPC-Derived Gliomas
scRNA-seq suggests that tumor OPCs in adult OPC-originated
gliomas may function as TICs given their strong stemness fea-
ture. Supporting this notion, our previous work using the im-
munopanning approach showed that PDGFR𝛼+ subpopulation
enriched tumor cells in nonadherent culture.[25] To further con-
firm whether these cells function as TICs in vivo, we performed
scRNA-seq on the cell line from the CKO_NG2-CreER tumor (Fig-
ure 1J). These results confirmed that both OPC-like and non-
OPC like cells coexisted (Figure 1K). PDGFR𝛼+ tumor OPCs also
enriched markers for division and stemness (Figure 1K and not
shown). We sorted tumor OPCs by flow cytometry based on their
surface expression of PDGFR𝛼 (Figure 1L,M), and validated that
PDGFR𝛼 high expression fraction not only enriched the tumor
cells growing in nonadherent culture condition (Figure 1N), but
also those more effectively initiating secondary tumors after or-
thotopically grafted in the NOD-SCID mouse brains (Figure 1O).
Thus, we conclude that tumor cells resembling OPC features
function as TICs in the OPC-derived glioma model driven by
Trp53 and NF1 mutations.
To further validate our mouse model work in human context,
we analyzed the tumor tissues from GBM patients. Constant with
the single cell sequencing and the immunohistological results
from previous studies,[9,25,27–32] we found the presence of Olig2+
tumor OPCs in human GBMs regardless the molecular subtypes
or mutations (Figures S2 and S3, Supporting Information). Sim-
ilar to that in the mouse model, many tumor OPCs underwent
active cell division, suggesting that they contributed to the pro-
liferation pool in human GBM (Figures S2 and S3A, Supporting
Information). We established primary GBM cell lines and found
numerous tumor OPCs (Figure S3A, right panel, Supporting In-
formation). Sorting of tumor OPCs based on their surface expres-
sion of PDGFR𝛼 showed that PDGFR𝛼 high fraction was the sub-
population to effectively grow in vitro (Figure S3B–D, Supporting
Information) and generated tumors in vivo (Figure S3E,F, Sup-
porting Information). This result nicely mirrors the mouse data
and suggests that tumor OPCs play critical roles in the progres-
sion of at least some human gliomas.
2.3. The IGF Signaling Axis Is Important to Sustain OPC-Like
TICs
To identify critical growth factor (GF) receptors for OPC-
originated gliomas, we evaluated the efficiency of a panel of
GFs in sustaining the nonadherent growth of mouse tumor
OPCs. IGF1 exhibited the strongest ability to sustain nonad-
herent cultures in GF-free media (Figure 2A,B). This observa-
tion can be repeated by independent cell lines (Figure S4A, Sup-
porting Information). As IGF2 and insulin exhibited much less
efficacy (Figure 2A,B), IGF1 likely stimulated OPC-like TICs
through the IGF1R.[33] This conclusion is supported by that small
molecule IGF1R inhibitors (Figure S4B–G, Supporting Infor-
mation), CRISPR-Cas9 (Figure 2N–P), shRNA (Figure S4H,I,
Supporting Information), and MicroRNA (Figure S4J–M, Sup-
porting Information)-based genetic approaches could effectively
suppress the growth of tumor OPCs stimulated by IGF1/2.
Surprisingly, despite PDGFR𝛼 was prominently expressed in tu-
mor OPCs and its activation has been believed to be essential
for normal OPCs, PDGF alone was not sufficient to support the
growth of tumor OPCs (Figure 2A,B; Figure S4A, Supporting
Information), suggesting the importance of the proper function
of IGF1R for the influx of growth signals mediated by multiple
RTKs beyond IGF1R. Indeed, PDGF and FGF2 was unable to res-
cue the growth of tumor OPCs after IGF1R was knocked down
(Figure S4H, Supporting Information). It should be noted that,
given that high concentration of insulin can also activate IGF1R,
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the minimal media used for nonadherent growth assay were de-
void of insulin, which was otherwise routinely added for glioma
cell culture in many studies.
In order to further delineate the role of IGF1R in tumor OPCs,
we reexamined the expression pattern of IGF1R in our scRNA-
seq dataset. In the mouse glioma cell line, IGF1R highly over-
lapped not only with the OPC marker PDGFR𝛼, but also with
those marking proliferation and stemness (Figure 2C). The ex-
pression of IGF1R in intact tumor tissues was independently
validated by the Western blots and in situ immunofluorescence
histochemistry (Figure S4N,O, Supporting Information). These
observations lead us to speculate that IGF1R may also function as
a TIC marker for gliomas. To validate this speculation, we isolated
OPC-like cells based on their surface level of IGF1R (Figure 2D).
Compared to those with minimal IGF1R expression (IGF1RLow),
the IGF1Rhigh fraction significantly enriched the tumor cells to
form spheres in vitro (Figure 2E) and to initiate tumors in vivo
(two independent cell lines, Figure 2F,G). Therefore, IGF1 sig-
naling axis likely plays essential roles in maintaining the stem-
ness of tumor OPCs both in vitro and in vivo.
2.4. IGF1R Knockout Suppresses the Malignant Transformation
of Adult OPCs
To ask whether IGF signaling pathway plays a role during glioma-
genesis in the physiological relevant context, we concurrently
knocked out IGF1R together with Trp53 and NF1 in adult OPCs
(termed CKO_NG2-CreER_IGF1R (flox/flox) model, Figure 2H).
Removal of both IGF1R alleles in adult OPCs significantly pro-
longed the survival of the model (Figure 2I). While less profound,
a similar phenotype was observed when one IGF1R allele was re-
moved, suggesting IGF1R has dosage effects on tumor initiation
and /or progression. We next examined the tumor incidence in
these mice upon the moribund stage. Consistent with the previ-
ous report,[8] a near-to-full penetrance of high-grade glioma was
found (Figure 2J). In rare cases, mice contracted sarcomas out-
side of the CNS, likely because of the expression of NG2-CreER
in non-CNS cells. In contrast, the glioma incidence significantly
decreased in the CKO_NG2-CreER_IGF1R (flox/flox) mice, indi-
cating that IGF1R deactivation restrained OPC transformation.
This conclusion was further confirmed by immunostaining at
165 days post injection (dpi) of tamoxifen, a time point when
most tumor mice showed undetectable symptoms (Figure 2K).
As CreER-LoxP system-mediated gene knockout cannot be
100% efficient, we suspected that the tumors developed in the
CKO_NG2-CreER_IGF1R (flox/flox) model were due to the in-
complete knockout of IGF1R allele in these tumor cells. To con-
firm this, we genotyped the IGF1R genomic locus. Indeed, de-
spite that a complete deletion of the single IGF1Rflox allele was
readily detected in the IGF1R (flox/+) mice (2/3 examined, Fig-
ure 2L), the IGF1R flox allele was either intact or with only partial
recombination in the IGF1R (flox/flox) tumors (N = 17, repre-
sentatives in Figure 2L). Supporting this notion, we found that
repeated administration of tamoxifen (twice a month), which
could further improve the recombination activity of NG2-CreER,
fully blocked glioma incidence in the IGF1R (flox/flox) mice (Fig-
ure 2J).We noted that the survival of these mice with repeated
tamoxifen administration was only minimally further extended
(Figure 2I). This can be explained due to the death caused by
other tumors out of the CNS through spontaneous loss of Trp53.
Supporting this notion, we found that when using the consti-
tutively activated NG2-Cre transgene in a different model, the
death of tumor mice was almost completely prevented (see be-
low in Figure 4). We therefore conclude that the proper function
of IGF1R is critical for OPC transformation.
To further address whether IGF1R plays a role in the pro-
gression of tumor OPCs in vivo, we utilized the cell line from
the CKO_NG2-CreER_IGF1R (flox/flox) model where IGF1R was
largely knocked out and examined its growth after grafted into the
brains of NOD-SCID mice. Our data showed that the tumor initi-
ating capacity of this line was largely impaired. However, reintro-
duction of exogeneous IGF1R could partially restore the tumor
initiating capacity of this cell line (Figure 2M). In parallel, we
performed in vivo competition assay by using the CRISPR-Cas9
approach (Figure 2N–P). Compared to tumor OPCs transfected
with nonspecific sgRNA, those with sgRNAs specific to IGF1R
were largely depleted from the tumor (Figure 2N). Correspond-
ingly, the death of tumor mice was partially delayed (Figure 2O).
Figure 2. The role of IGF1R in the initiation and progression of the OPC-derived glioma model. A,B) Representative images (A) and quantification (B)
of sphere formation by tumor OPCs in the presence of different growth factors (GFs) as indicated. EGF, epithelial growth factor; FGF, basic fibroblast
growth factor; HGF, hepatocyte growth factor; NT-3, neurotrophin-3; BDNF, brain-derived neurotrophic factor; GH, growth hormone. All growth factors
were provided as 10 ng mL−1. Scale bar: 100 µm. C) The projection of indicated genes on the tSNE map of a tumor OPC cell line that is also shown
in Figure 1J. D) The representative FACS plot and Western blots showing the expression of IGF1R on mouse OPC-like glioma cells. E) In vitro sphere
assay of OPC-like glioma cells based on their surface IGF1R expression sorted by FACS. Scale bar: 100 µm. F,G) The survival curves of mice grafted with
IGF1R high/low OPC-like glioma cells fractions. (F) and (G) are from two independent cell lines, N = 6 mice for IGF1Rhigh group and N = 5 mice for
IGF1Rlow group in (F), N = 5 mice for IGF1Rhigh group and N = 6 mice for IGF1Rlow group in (G). H) The genetic configuration of the CKO_NG2-CreER
mouse model with conditional IGF1R knockout. I) Survival curves for the three mouse models as indicated. The median survival times are indicated by
the dashed line. For the repeated TAM group, the mouse model was given tamoxifen twice a month following the first round of tamoxifen treatment at
postnatal (P) day 31-P35. For the other three groups, tamoxifen was given only from P31-P35. J) Tumor incidences in the three mouse models at the
endpoint of analysis from (I). The same groups of mice were used for calculating survival curves in (I) and tumor incidence in (J), ND: Not determined.
K) Representative images of brain sections from the CKO and CKO-IGF1R (flox/flox) mice immune-stained as indicated. The dashed line demarcates
the tumor boundary. T, tumor. Scale bars: 1 mm (gross images), 100 µm (zoom-in section). L) Genotyping data from paired normal and tumor tissues
from the three mouse models indicated. N, normal. T, tumor.M) Survival curves of the NOD-SCID mice orthotopically grafted with the tumor cells as
indicated. The IGF1R KO+ rescue cells were the ones from the IGF1R KO tumor OPCs stably transfected with the lentiviral vector that overexpressed
IGF1R. The expression/absence of the IGF1R protein from these cells was validated by the western blots, N = 7 mice for CKO and IGF1R KO group, N
= 5 mice for IGF1R KO + rescue group. N–P) Knocking out of IGF1R by the CRISPR-Cas9 approach. The histological analyses (N) of the tumor sections
from these tumors as shown in (O). The survival curves (O) of the NOD-SCID mice grafted with the indicated tumor cells. FACS analysis (P) confirmed
the decreased expression of surface IGF1R protein. Scale bar: 100 µm in (N), N = 6 mice for sgRNA-Ctrl group, N = 8 mice for sgRNA-IGF1R group.
Mean ± SEM. *p < 0.05, **p<0.01, ***p < 0.001.
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The partial knockout of IGF1R was confirmed by the FACS assay
at the protein level (Figure 2P). Taken together, these observa-
tions demonstrate that deletion of IGF1R severely compromises
the progression, and likely also the initiation, of OPC-originated
glioma.
2.5. Knockout of IGF1R Impairs the Growth and Promotes the
Differentiation of Mutant Adult OPCs But Minimally Affects
Normal OPCs at the Pretransforming Stage
We next set out to determine whether IGF1R deactivation sup-
pressed the transformation of mutant OPCs at the pretransform-
ing stage through compromising their capacity to proliferate and
differentiate into mature oligodendrocytes. The proliferation rate
of mutant OPCs at two time points, corresponding to the acute
and long-term stages during OPC tumorigenesis (Figure 3A,B),[8]
was determined by BrdU incorporation. Consistent with the pre-
vious report,[8] we found that mutant OPCs initially experienced a
transient elevation of their proliferation rate after acquiring mu-
tation (compared the first vs the third bars in Figure 3C), and
then the proliferation of these mutant cells declined to the level
of their normal control (compare the first vs the third bars in Fig-
ure 3D, and the first bars between Figure 3C,D). IGF1R knock-
out decreased the proliferation of mutant OPCs at both stages in
various brain regions, with the long-term stage becoming more
prominent (the first vs the second bars in Figure 3C,D). In com-
bination of two cellular markers, PDGFR𝛼 and CC1, to delineate
subpopulations throughout the OPC lineage (Figure 3F), we fur-
ther revealed that IGF1R knockout promoted the differentiation
of mutant OPCs at the pretransforming stage (Figure 3G).
In contrast, we found that knockout of IGF1R minimally affect
the proliferation (compared the third and the fourth bars in Fig-
ure 3C,D, representative images in Figure 3E) or differentiation
potential (Figure 3G) of wild-type OPCs within the same obser-
vation window. In fact, WT-NG2-CreER_IGF1R (flox/flox) mice
manifested no detectable abnormality up to 400 dpi (data not
shown), further supporting that IGF1R is not essential for the
physiology of normal adult OPCs. Therefore, it appears that the
impacts of IGF1R knockout on mutant OPCs were specifically
associated with the oncogenic state but not the intrinsic identity
of their normal cell-of-origin.
2.6. MADM Reveals That IGF1R Knockout Preferentially Affects
Mutant OPCs in a Mosaic Context
In patients, only a small number of normal cells acquired ini-
tial mutations. Therefore, we asked whether, in an in vivo con-
text where mutant OPCs are generated sparsely, knockout of
IGF1R preferentially suppresses the overproliferation of mutant
OPCs compared to their surrounding normal siblings. To ad-
dress this question, we leveraged a genetic mouse model termed
Mosaic Analysis with Double Markers (MADM),[7,34] which we
have previously used to mimic sporadic somatic mutagenesis
in glioma patients (see also working scheme in Figure S5A,
Supporting Information).[7] In the MADM-Mutant model (Fig-
ure 4A), mitotic recombination mediated by the NG2-Cre trans-
gene enables pairs of GFP-labeled mutant and tdTomato-labeled
wild-type OPCs to be generated simultaneously from unlabeled
heterozygous OPCs. As a control, we generated a MADM-WT
model in which both green and red OPCs possessed the wild-type
genotype (Figure 4B). To knock out of IGF1R among all OPCs
with distinct genotypes, we introduced the homozygous IGF1R
(flox/flox) alleles into MADM-Mutant to generate the MADM-
Mutant-IGF1R model (Figure 4C).
Consistent with our previous observation,[7] the abundance of
mutant OPC-lineage cells in the MADM-Mutant model progres-
sively increased from 0.373% at P5 up to 55.12% at P60 (Fig-
ure 4D,I; Figure S5B, Supporting Information). Accordingly, the
average G/R ratio (the relative number of green Mutant to red WT
cells) drastically increased from 1.82 at P5 to 528.00 at P60 (Fig-
ure 4G). As the G/R ratio reflects the severity of the overexpan-
sion of mutant OPCs compared to their normal siblings, these
results demonstrate that mutant OPCs possessed a much more
elevated proliferation rate compared to their surrounding WT
siblings. In contrast, in the MADM-WT model, the relative abun-
dance of green WT cell always remained below 0.5% of all OPC-
lineage cells (Figure 4E,I) and the average G/R ratio was close
to one (Figure 4G). Notably, the total number of OPC-lineage
cells was not significantly different between the two models at all
four developmental time points examined (Figure 4H), suggest-
ing that mutant OPCs increased their number at the expense of
normal OPCs, possibly through cell-to-cell competition.
In stark contrast, we found that the overexpansion of mu-
tant OPCs was significantly suppressed after IGF1R was knocked
out (Figure 4F,I). Knockout of IGF1R also significantly reduced
the G/R ratio, particularly at the later time point such as P60
(Figure 4G). This latter observation further supports that mu-
tant OPCs are more sensitive than their WT siblings to IGF1R
deprivation (otherwise, the G/R ratio should not be affected by
the IGF1R status). Together with the findings that no signifi-
cant change in the total number of OPC-lineage cells was de-
tected among the three MADM models at all developmental time
points except for P5 (Figure 4H), we propose that IGF1R deacti-
vation affects mutant and adjacent WT OPCs in opposite ways:
it suppresses the overexpansion of mutant OPCs but recovers
the number of normal OPCs, like by rebalancing the growth
fitness between the two genotypes of OPCs. Furthermore, we
also found that, although MADM-Mutant model fully developed
glioma around 8 months, the MADM-Mutant-IGF1R model ex-
hibited no obvious symptoms up to 400 days (Figure 4J–L). These
observations, together with those in Figure 2 by using a distinct
model system, further support that IGF1R is critical for OPC
transformation in vivo.
2.7. Knockout of IGF1R Minimally Affects Adult Mutant NSCs
until They Commit to the OPC Identity
Does the identity of the cells among the development hierarchy
into which the driver mutations were initially introduced (we
named as the cell-of-mutation to distinguish the cell-of-origin,
although both concepts are not necessarily mutually exclusive)[7]
also determine the sensitivity of IGF1R targeting? It is well
known that NSCs can give rise to OPCs throughout life.[35] Ac-
cordingly, knocking out of Trp53 and NF1 directly in NSCs, as
in OPCs, can efficiently generate high-grade gliomas.[4,7] Given
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Figure 3. The impacts of IGF1R knockout on the growth of mutant and normal OPCs at the pretransforming stage of tumor development. A,B) Schemat-
ics showing the tamoxifen (TAM) and BrdU treatment schedules for the mice analyzed either acutely (A) or long-term (B). C,D) The quantification of
BrdU+ cells among all the tdTomato labeled Olig2+ cells in the brain regions of mice with the four different genotypes shown, after either the C) acute or
D) long-term experiments. Please refer to Table S7, Supporting Information, for all raw quantification data, N = 3 mice for each group. E) Representative
images of the brain sections from the olfactory bulb region after the long-term experiment. The arrows indicate cells coexpressing markers. The insets
show a zoom-in image of the indicated cells. Scale bar: 50 µm. F) Images showing the distinct cell types along the OPC lineage, where OPCs were
defined as PDGFR𝛼+ and CC1−, newly formed oligodendrocytes as PDGFR𝛼+ and CC1+, and mature oligodendrocytes as PDGFR𝛼− and CC1+. Scale
bar: 30 µm. G) The relative abundance of the indicated subpopulations from the corpus callosum after the acute and long-term experiments. N = 3 mice
for each group. Mean ± SEM. t-test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns, no significance.
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Figure 4. IGF1R knockout in a MADM glioma model. A–C) Genetic configurations of the OPC-lineage cells in the MADM-based models. Notably, in
(C) all OPC-lineage cells, not only those labeled by MADM, were IGF1R (-/-). MADM-labeling was induced by the NG2-Cre. The color for each genotype
indicates the expression of the fluorescent protein(s) in the cell. Red, tdTomato; green, EGFP; yellow, both tdTomato and EGFP; gray, no fluorescent
protein expressed (nonlabeled). D–F) The abundance of each genotype of Olig2+ cells among all the OPC-lineage cells in the D) MADM-Mutant, E)
MADM-WT, and F) MADM-Mutant-IGF1R models at the four developmental time points as indicated. The color codes of the cells in (D), (E), and (F)
are the same as those in (A), (B), and (C), respectively. The data for each group were the average from N = 4 mice. G) The G/R ratios of MADM-labeled
Olig2+ cells from the brains of the three models analyzed at the four development time points indicated, N = 4 mice for each group. H) The density of
all OPC-lineage cells from the mice in (G), N = 4 mice for each group. I) Representative images of the cortical brain sections from (A–C) at P60. Olig2
was used to mark all OPC-lineage cells. Scale bar: 50 µm. J) The representative images of the brain sections from the indicated models at the end-point
stage. Scale bars: 1 mm (gross images), 100 µm (zoom-in section). K,L) The survival curves (K) and the tumor incidences (L) of the models as indicated.
Of note, the IGF1R allele of the only tumor mice from the MADM-Mutant-IGF1R model was intact based on the IGF1R genotyping (not shown), ND:
Not Determined. Please refer to Table S7, Supporting Information, for all raw quantification data in Supporting Information. Mean ± SEM. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001, ns, no significance.
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that adult NSCs and OPCs are in the same development hierar-
chy during gliomagenesis but possess distinct cell identities, a
genetic model using adult NSCs as the glioma cell-of-mutation
will help to address this question.
We therefore generated a pair of mouse models with knock-
outs of Trp53 and NF1 with/without IGF1R ablation in adult
NSCs using a Nestin-CreER transgene. The specificity of this
transgene to label adult NSCs, but not directly to OPCs, was vali-
dated in Figure S6, Supporting Information. We detected a clear
accumulation of mutant OPCs in the brain of the CKO_Nestin-
CreER model after tamoxifen treatment (from 13 to 43 dpi, three
time points examined), particularly at the locations next to the
SVZ, which was otherwise rarely seen in the WT control brain
(Figure S7, Supporting Information). These observations, to-
gether with the previous findings by us and others,[7,36,37] support
the notion that, upon acquiring mutations, adult NSCs preferen-
tially give rise to OPCs, which then expand, similar to the sit-
uation where the same mutations were directly introduced into
OPCs (as illustrated in Figure 5A).
As in adult normal NSCs and normal OPCs,[38] but not mu-
tant OPCs, at all three time points examined (Figure 5B), IGF1R
knockout in mutant adult NSCs did not significantly affect the
proliferation rate or the number of these cells (Figure 5C,D,I).
Even with the total number of BrdU+ cells as criteria, which in-
cluded adult NSCs and their fast dividing progenitors, no alter-
ations were detected (Figure 5E).The number of mutant granule
cells in the olfactory bulb was not affected either (Figure 5F), fur-
ther supporting that IGF1R deactivation minimally affects the
self-renewal of mutant adult NSCs in vivo. In contrast, when we
examined mutant OPCs in these brains, we found a significant
decrease in their proliferation when compared with their IGF1R-
intact counterparts in the CKO_Nestin-CreER brains (Figure 5G–
I). This difference has already become prominent at 13 dpi, the
earliest time point that we could detect the emergence of signif-
icant numbers of mutant OPCs. These data clearly demonstrate
that adult pretransforming cells manifesting the cell identity of
OPCs, but not NSCs, respond to the loss of IGF1R, at least read
by their proliferation rates.
To further confirm this conclusion, we isolated adult NSCs
from both models and assayed their self-renewal and differentia-
tion potential ex vivo (Figure 5J). Consistent with the in vivo data,
we found that knockout of IGF1R did not affect the size of neu-
rospheres (Figure 5J). However, the potential of NSC differentia-
tion toward OPC lineage was significantly suppressed in IGF1R-
KO mutant NSCs compared to their IGF1R intact counterparts
(Figure 5K,L). The distinct susceptibility of NSCs and OPCs to
IGF1R knockout cannot be explained as the differences of their
IGF1R expression, as both types of cells, regardless of aquiring
mutations, expressed similar level of IGF1R as detected by qRT-
PCR (data not shown). Together, we propose that, in addition to
the oncogenic state, the identity of the cell upon acquiring driver
mutations is also crucial in the susceptibility to IGF1R targeting.
2.8. The IGF1R Is Preferentially Activated in Proliferating Tumor
OPCs from Human Gliomas
To directly determine whether the IGF1R is activated in human
tumor OPCs, we analyzed the tumor tissue from a GBM patient
with the classical subtype (Figure S3A, Supporting Information).
Similar to our mouse model studies shown in Figure S4N, Sup-
porting Information, both total IGF1R and pIGF1R were found to
be present in these human tumor OPCs (Figure 6A). pIGF1R was
most frequently detected in tumor cells expressing both Ki67 and
PDGFR𝛼. The prominent cytoplasmic localization of pIGF1R
(Figure 6A,B; Figure S8A, Supporting Information), as shown
in other type of tumors previously reported,[39] further supports
the activation of IGF1R in these cells. Similar results were ob-
served in multiple GBMs and lower-grade human gliomas (N
= 5 for each grade, Figure S8B–D, Supporting Information). Of
note, while pIGF1R+ cells represented only a small fraction of
total cells, most were tumor OPCs. Moreover, the percentage of
proliferating tumor OPCs among all pIGF1R+ cells was positively
associated with the tumor grade (Figure S8D, Supporting Infor-
mation). Therefore, we conclude that in human gliomas, particu-
larly GBMs, IGF1R-mediated signaling can be activated in tumor
OPCs that are undergoing proliferation.
2.9. IGF1R Is Important for the Growth of Human Tumor OPCs
Both In Vitro and In Vivo
We next determined whether human tumor OPCs require IGF1R
and are sensitive to IGF1R inactivation. As long-term culture of
GBM cells in either serum or stem cell media with EGF may
lead to the loss of tumor OPCs,[25] we reestablished primary
GBM cell lines de novo or directly used those freshly isolated
from surgical samples to study tumor OPCs from patients. We
first established a simple approach to enrich tumor OPCs based
on the anti-PDGFR𝛼 immunopanning technique (Figure 6C).
Immunostaining (Figure 6D), RNA-seq, qPCR analyses and ss-
GSEA (Figure S9A–C, Supporting Information) at the transcrip-
tomic level confirmed successful enrichment of human tumor
OPCs by this approach. Interestingly, the gene ontology (GO)-
term analysis suggested that the genes involved in both IGF and
PDGF signaling pathways were consistently enriched in tumor
OPC fraction (N = 4 GBMs, Figure S9D, Supporting Informa-
tion), highlighting the intimate interaction between these two
pathways in human tumor OPCs.
We next selected a tumor sample that contained numerous tu-
mor OPCs (Figure 6E; Figure S3A, Supporting Information) de-
spite molecular classification confirmed its mesenchymal sub-
type GBM (Figure 6F). Both WB (Figure 6G) and immunofluores-
cence staining (Figure S3A, Supporting Information) confirmed
that activation of IGF1R in this tumor, mainly in tumor OPCs.
Similar to that in the mouse model, immunopanning enriched
tumor OPCs were the main fraction to grow in insulin-free min-
imal media regardless the growth factor provided (Figure 6H,I).
Interestingly, EGF/FGF did not support the nonadherent growth
of either fractions from this line (Figure 6I).
We further conformed that the observation could be repeated
by multiple GBM samples harboring a diverse variety of ge-
netic aberrations and were stratified into distinct subtypes, in
either nonadherent or monolayer cultures (Figure S10, Support-
ing Information). Akin to their mouse counterparts, human tu-
mor OPCs exhibited a strong preference for IGF1. Importantly,
IGF1R inhibitor OSI-906 not only suppressed sphere forma-
tion induced by IGF1, but also that by other growth factors
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Figure 5. The susceptibility of NSCs and their progeny toward IGF1R targeting. A) Schematic showing the differentiation pattern of adult NSCs after
acquiring the initial mutations in the mouse model. B) The schedules of tamoxifen (TAM) and BrdU administration for the three time points analyzed.
C) The percentage of BrdU+ cells among all tdTomato+ and Sox9+ mutant cells in the SVZ from the two mouse models at three different time points as
indicated. D,E) The density of BrdU+, tdTomato+ and Sox9+ proliferating mutant NSCs (D) and the density of all BrdU+ proliferating cells (E) in the SVZ
from the two mouse models at three different time points as indicated. F) The percentage of mutant granule neurons among all neurons in the OB from
the two models indicated. G,H) The percentage and density of proliferating mutant OPCs in the CC next to the SVZ (region 6 in Figure S7C, Supporting
Information). L-SVZ, the lateral subventricular zone; CC, the corpus callosum. I) Representative images of the brain sections from the two models at 43
dpi. Scale bar: 50 µm for the NSC panels, 100 µm for the OPC panels. J) Ex vivo culture of mouse adult NSCs with the genotypes as indicated. Scale bar:
200 µm for the left panel, 100 𝜇m for the right panel. K,L) Representative images (K) and the quantification (L) of in vitro differentiation of adult NSCs
as indicated. 2% serum was used to induce the differentiation of NSCs. Scale bar: 100 µm in (K). Mean ± SEM.*p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001, ns, no significance. N = 4 mice for all groups except for the CKO-Nestin-CreER group at 43 dpi in (C)–(E), (G), and (H), where N = 3.
Please refer to Table S7, Supporting Information, for all raw quantification data in Supporting Information.
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(Figure S10, Supporting Information). Similar results were ob-
served by using PPP (Figure S10J, Supporting Information) and
RNAi-based genetic approach (Figure 6N,O), excluding the pos-
sibility that the observed inhibition of tumor spheres was caused
by the off-target effect of the inhibitors.
To further determine the role of IGF1R in the growth of hu-
man OPC tumor cells in vivo, we acutely transfected patient-
derived glioma cells with Piggybac (PB) transposon vectors
encoding multiplex miRNAs against different sites of IGF1R
(Mir-IGF1R) or against Luciferase (Mir-Luc) (Figure 6J,K). The
design to include multiple miRNAs targeting distinct sequences
in the same transcript could maximally increase the knockdown
efficiency. As the tumor cells were derived directly from the pa-
tient (Figure 6L) with minimal exposure to in vitro conditions
(less than 12 h) and electroporation delivered vectors into all
tumor cell types equally, this patient-derived xenograft (PDX)
model offered a unique opportunity to evaluate the effects of
IGF1R deprivation on OPC-like and non-OPC-like cells in the
same tumor, which helped to address the question whether dis-
tinct subpopulation of in the same tumor possessed the same
susceptibility to IGF1R targeting. The knockdown of IGF1R was
validated by the qPCR assay (Figure 6M). The results show that,
not only did the relative abundance of Mir-IGF1R-expressing tu-
mor cells (normalized to nPhiYFP+ cells serving as the internal
reference in the same tumor) decrease (Figure 6P), but the per-
centage of Olig2+ cells among all Mir-IGF1R-expressing tumor
cells also significantly decreased when compared to the nonspe-
cific control (Figure 6Q). Similar results were also observed in
another two sets of PDX models with tumor cells derived from
different GBM patients (data not shown). These results indicate
that IGF1R targeting suppresses the growth of human GBM cells
in vivo and that tumor OPCs are more susceptible to IGF1R tar-
geting. These results collectively substantiate our conclusion that
human tumor OPCs among tumor hierarchy are preferentially
susceptible to IGF1R targeting, paralleling to tumorigenic pro-
cess shown in the mouse model studies.
Finally, we tested whether IGF1R could function as the TIC
markers for human glioma cells. We found that IGF1R-based
sorting enriched the human GBM cells to form spheres in vitro
(Figure 6R) and initiate tumors in vivo (Figure 6S). Therefore, we
conclude that IGF1R is critical for the stemness of human OPC-
like tumor cells both in vitro and in vivo, nicely recapitulating our
mouse work in Figure 2. Notably, IGF1R may be considered as a
TIC marker independent of the OPC feature in some cases. The
TICs in a classical human GBM stem cell line T387,[3] which was
completely absent of PDGFR𝛼, can also be enriched based on
their IGF1R expression (Figure 6T).
2.10. IGF1R Is a Key Player That Controls the Influx of Growth
Signals into Tumor OPCs
We next investigated the molecular mechanisms by which IGF1R
preferentially regulates the growth of tumor OPCs and why other
GFs such as PDGF cannot effectively rescue the growth of tumor
OPCs without the proper function of IGF1R. We first examined
the dynamic response of tumor OPCs to IGF1 or PDGFAA stim-
ulation. As shown in Figure 7A, compared to PDGFAA, IGF1
elicited a much stronger and more durable activation of the PI3K-
Akt signaling, indicating that IGF1 is more potent than PDGFAA
to sustain the PI3K-Akt pathway in these cells. Instead, PDGFAA
was more effective in activating ERK. Same results could be ob-
served by using mutant OPCs at the pretransforming stage (data
not shown). Consistent with previous report by using different
GBM cell lines,[15] we found that tumor OPCs employed more
on PI3K-Akt signaling than the Ras-Raf-MEK-ERK signaling cas-
cade to support their growth (Figure 7B; Figure S11A,B, Support-
ing Information). This suggests that IGF1R may regulate OPCs
mainly via the downstream PI3K-Akt pathways throughout the
tumor development stages.
Intriguingly, in our lineage tracing experiment at the pretrans-
forming stage, we have observed that the proliferation rate of
IGF1R-deficient mutant OPCs was even lower than that of wild-
type OPCs at the long-term stage (compare the second vs the
third bars in Figure 3D). This implicated that mutant OPCs relied
more on IGF1R signaling to sustain their growth. If the PI3K-Akt
axis is involved in this process, we would expect that inactivation
of IGF1R should induced more profound effect in mutant OPCs
than the wild-type ones on the components of PI3K-Akt axis. To
prove this hypothesis, we enriched the WT and Trp53/NF1-null
mutant OPCs from neonatal mouse brains (Figure 7C) and in-
deed showed that in culture IGF1R inhibitor OSI-906 only par-
tially inhibited the PI3K-Akt cascade in WT OPCs but completely
Figure 6. The susceptibility of human tumor OPCs toward IGF1R targeting. A) Representative images showing that IGF1R and pIGF1R are expressed
in proliferating tumor OPCs from a GBM sample. The arrows indicate the cells coexpressing markers indicated. The low power images are provided
at the bottom row to show no bias of imaging collection. Z-axis orthogonal views are provided in zoom-in images to confirm the colocalization of the
markers. Scale bars, 20 µm in the top and middle rows; 100 µm in the bottom row. B) Zoom-in of images to show the expression of the indicated
markers in one tumor OPC. The fluorescence intensity across the middle plane of the cell is shown. Scale bars, 3 µm. C) Schematic diagram showing the
immunopanning method used to enrich human tumor OPCs. D) Representative images showing that PDGFR𝛼-positive cells were enriched in the panned
fraction. Conversely, GFAP-positive tumor cells were largely depleted but appeared in the supernatant fraction. Scale bar: 400 µm. E–G) The MRI images
(E), subtype analysis (F), and Western blots (G) of indicated proteins for a human GBM (#H5). Additional histological and pathological information
of this tumor case can be found in Figures S3 and S8, Supporting Information. H,I) Representative images and the quantification from a sphere assay
of a primary human GBM cell line (#H63) treated with the indicated growth factors. S: supernatant fraction, P: immunopanned tumor OPCs fraction.
IGF1, 10 ng mL−1; EGF, 50 ng mL−1; FGF, 20 ng mL−1; PDGF, 20 ng mL−1. OSI-906, 0.5 µm. Scale bar: 25 µm in (H). J) Schematic diagram showing the
strategy to genetically knock down IGF1R in patient-derived xenograft (PDX) models. K) Piggybac (PB) transposon vectors encoding multiplex miRNAs
against different sites of IGF1R (Mir-IGF1R) or against Luciferase (Mir-Luc). L) The MRI image of the fresh tumor sample used in (P,Q). M) The knock
down of IGF1R was validated by qPCR. N,O) The quantification (N) and the image (O) of tumor spheres after IGF1R was knocked down by MirRNA.
Scale bar: 100 µm in (O). P,Q) The quantification results from the PDX model shown in (L), N = 3 mice for each group. R,S) The sphere assay (R) and
the survival curves (S) of NOD-SCID mice grafted with human OPC-like glioma cells (#H5) based on their surface IGF1R expression. Scale bar: 100 µm
in (R), N = 5 mice for IGF1Rhigh group and N = 6 mice for IGF1Rlow group in (S). T) The survival curve of NOD-SCID mice grafted with a human glioma
stem cell line based on their surface IGF1R expression. Of note, this cell line does not express PDGFR𝛼, N = 7 mice for IGF1Rhigh group and N = 6 mice
for IGF1Rlow group. Mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 7. The crosstalk of IGF1R and PDGFR𝛼 pathways in tumor OPCs. A) Activation of signaling pathways in tumor OPCs after stimulation with IGF1
(20 ng mL−1) or PDGFAA (20 ng mL−1) for the indicated periods. OE, overexposed. The red asterisk indicates the presence of pIGF1R after PDGFAA
stimulation for 120 min. B) Sphere assay for mouse tumor OPCs treated with the indicated inhibitors. Spheres were formed in the presence of 10 ng
mL−1 IGF1. Mean ± SEM. ***p < 0.001. C) Representative images showing purified mutant and WT OPCs used for the biochemical analysis in (D). Scale
bar: 50 µm. D) The response of WT and Trp53/NF1 double mutant OPCs to IGF1 in the presence or absence of OSI-906. E) Activation of indicated RTKs
in mouse tumor OPCs after stimulation with IGF1 for the indicated periods. F) Activation of indicated RTKs in human tumor OPCs after stimulation with
IGF1 for the indicated periods. G,H) Co-IP assay to determine the interaction between mouse PDGFR𝛼 and IGF1R. Exogeneous expression of mouse
PDGFR𝛼 and IGF1R in either HEK293 cells (G) or the endogenous PDGFR𝛼 and IGF1R in mouse tumor OPCs (H) was performed separately. I) Co-IP
assay to determine the interaction between exogenously expressed human PDGFR𝛼 and IGF1R in HEK293 cells. J) The effect of OSI-906 on IGF1 (20 ng
mL−1) and/or PDGFAA (20 ng mL−1) signal transduction. The cells were analyzed 2 h after OSI-906 (0.5 µm) treatment. K) IGF1R-null mouse tumor
OPCs responded to the stimulation of growth factors (20 ng mL−1) as indicated. OE, overexposed. L) Schematic showing the hypothetical crosstalk
between IGF1R and PDGFR𝛼 in tumor OPCs.
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blocked its activity in mutant OPCs (Figure 7D). Interestingly, the
same phenotype can also be observed in WT and Trp53/NF1-null
MEFs (Figure S11I, Supporting Information). Therefore, this ob-
servation, together with the in vivo studies (Figures 3 and 4),
strongly suggest that the oncogenic state can reprogram the sig-
naling network, and drive the mutant OPCs to depend more, if
not solely, on IGF1R-mediated influx of extracellular signals to
sustain the PI3K-Akt signaling.
It has been puzzled that tumor OPCs do not need PDGF for
their growth in vivo, although wild-type OPCs absolutely require
it. Unexpectedly, we found that, in addition to efficiently activate
IGF1R, IGF1 also induced the phosphorylation of PDGFR𝛼 in
mouse tumor OPCs (Figure 7E). This observation could be also
observed in human tumor OPCs (Figure 7F). Therefore, our find-
ing leads to the novel proposition that tumor OPCs may use
IGF1R to activate both pathways for their maximal fitting in the
in vivo condition. As the activation of PDGFR𝛼 occurred within
2 min after IGF1 treatment (Figure 7E,F), the transactivation
of PDGFR𝛼 was likely through the protein-protein interaction
at the post-translational level. Coimmunoprecipitation (Co-IP)
assay confirmed that PDGFR𝛼 and IGF1R from mouse tumor
OPCs could form complex (through both ectopic expression and
directly testing the endogenous proteins), either through direct
or indirect interaction (Figure 7G,H). Similar results could be ob-
tained in human context (Figure 7I).
On the other way around, our pharmacological and RNAi ex-
periments demonstrated that even saturated amount of PDGFAA
could not support tumor OPCs to growth without the proper
function of IGF1R (Figure 6H; Figures S4H and S10, Support-
ing Information). At the molecular level, we found that IGF1R
inhibitor OSI-906 not only suppressed the activation of the PI3K-
Akt cascade stimulated by IGF1, but also that by PDGFAA (Fig-
ure 7J). A similar result was obtained using a different IGF1R
inhibitor, genetic knockout of endogenous IGF1R, in multiple
mouse and human primary glioma cell lines with different ge-
netic mutations (Figure S11C–G, Supporting Information). In-
terestingly, OSI-906 did not affect PDGFAA-induced PI3K acti-
vation in human HEK293 cells (Figure S11H, Supporting Infor-
mation), suggesting that this phenomenon depends on cellular
contexts. Of note, we found that in IGF1R-knockout tumor OPCs,
PDGFR𝛼 protein lever was significantly decreased (Figure 7K),
raising the interesting possibility that the interaction between
IGF1R and PDGFR𝛼 may help to stabilize PDGFR𝛼 proteins and
facilitate the PDGFR𝛼-mediated signaling, and therefore inacti-
vation of IGF1R by degradation may have more profound effects
than merely blocking its kinase activity. Taken together, these re-
sults support that IGF1R is a key player that controls the influx of
growth signals into tumor OPCs by two folds of mechanism: 1)
in the context without PDGF, the activation of IGF1R can activate
PDGFR𝛼 at the same time; and 2) in the context with PDGF, the
action of PDGFR𝛼 requires the existence of IGF1R (as proposed
in Figure 7L).
2.11. A Novel Blood–Brain Barrier Penetrable IGF1R Inhibitor
Efficaciously Suppresses the Propagation of GBM Cells Grafted
into the Mouse Brain
To pave the way for translating these findings into developing
an IGF1R-targeted GBM therapy, we pursued lead optimization
for the well-studied IGF1R inhibitor picropodophyllin (PPP, or
AXL1717) that has been tested in clinical trials with tolerable
systemic toxicity but exhibits poor penetration across the mouse
blood–brain barrier (BBB; as shown in Figure 8B,C).[23,40,41] We
designed and tested a series of novel PPP analogs (Figure 8A),
and identified compound PB-020 as a promising candidate for
further development based on multiple criteria including BBB
penetration capability assessed by biomarkers (Figure 8B) or di-
rectly measured by HPLC (Figure 8C), in vitro drug efficacy in
cultured adherent glioma cells (Figure 8D) and tumor spheres
(Figure 8E). Remarkably, oral administration of PB-020 not only
effectively suppressed the propagation of tumor OPCs that had
been orthotopically grafted into mouse brains but also prolonged
the survival of tumor mice (Figure 8F,G). Furthermore, long-
term oral administration of PB-020 showed no obvious toxicity
to tumor mice (Figure 8H,I; Figure S12, Supporting Informa-
tion). PB-020 inhibited the proliferation of tumor OPCs more
than their non-OPC counterparts (Figure 8J). These observations
not only demonstrate the potential value of newly developed BBB-
penetrable oral IGF1R inhibitors in GBM treatment, but also
substantiate our above conclusion that tumor OPCs are prefer-
entially susceptible to IGF1R targeting.
To elucidate the interaction mode between PB-020 and the
IGF1R, we performed a molecular docking simulation by po-
sitioning PB-020 into the ligand-binding pocket of IGF1R apo
structure (Figure 8K).[42] When docked in the same manner, PB-
020 and PPP took similar binding modes to the pocket. Based on
the full length structures of IGF1R in the presence or absence of
its ligand IGF1,[43] the ligand-binding pocket used for the dock-
ing will have a conformational change to adopt IGF1 (Figure 8L).
Therefore, both PB-020 and PPP likely block the binding of IGF1
to IGF1R by occupying the ligand-binding pocket to competi-
tively inhibit the activation of IGF1R.
3. Discussion
In this study, we report that the susceptibility of glioma cells to
IGF1R targeting is determined not only by its oncogenic state,
but also by its cell identity/state within the hierarchy of tumor
development. Along the differentiation route of NSCs to more
differentiated progenitors such as OPCs, distinct cell types po-
sitioned on the developmental hierarchy respond differently to
IGF1R upon acquiring the oncogenic insults. Deactivating the
IGF1R mainly impacts on mutant OPCs but minimally affects
the growth of normal adult OPCs or NSCs. Molecularly, high sen-
sitivity of mutant and cancer cells with the OPC feature toward
IGF1R targeting likely stems from the intimate coupling between
IGF1R and PDGFR𝛼, as the coexpression of both RTKs largely
occurs in OPCs in the brain.
Recent studies suggest that tumor OPCs widely exist in hu-
man gliomas.[9,25,27–32] These cells have been reported to con-
tribute to the proliferation pool and may exhibit distinct mi-
gration/infiltration behaviors in vivo.[26,28,30] Our scRNA-seq and
grafting studies suggest tumor OPCs residue at the apex of
the developmental hierarchy and likely contribute as the ma-
jor proliferation pool in mouse gliomas with OPC as the cell-
of-origin. This conclusion can be recapitulated at least in some
human GBMs (this study and[25]). Therefore, OPC-related cells,
in addition to playing roles in gliomagenesis, likely represent an
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Figure 8. A new generation of oral IGF1R inhibitor that can penetrate the blood–brain barrier. A) Chemical evolution of PB-020. B) The Western blots of
the major pathways in the brain tissues from the mice that orally treated with the vehicle or the inhibitors as indicated. C) HPLC analyses of the brain
extracts from the mice orally treated with the compound as indicated. Mice were dosed by gavage with 50 mg kg−1. At predosing (0 h) and different
post-dosing time points, the mice were euthanized, and their blood and brain samples were processed for HPLC analysis. D) IC50 of five lines of adherent
glioma cell lines as indicated (N = 3, mean ± SD). Among them, U87MG, DBTRG, and KNS-81 lines were maintained in 10% serum. Mouse glioma
cell line Ms1483 and human GBM cell line #H5 were maintained in the stem cell media. E) The sphere assay of mouse tumor OPCs treated with the
indicated inhibitors (0.5 µm) and 20 ng mL−1 IGF1. Western blots showing that PB-020 also decreased the total level of both IGF1R and PDGFR𝛼. F)
Survival curves of NOD-SCID mice orthotopically grafted with mouse tumor OPCs and orally treated with vehicle, PPP or PB-020. N = 5 mice for vehicle
and PPP group, N = 6 for PB-020 group. G) Representative images of the brain sections from (F). Scale bar: 100 µm. H,I) Photos of mice and the H&E
staining of the brain sections (including the hippocampus) treated with the vehicles or inhibitors as indicated. Scale bar: 400 µm in (I). J) The percentage
tumor OPCs (Olig2+) among proliferating (top) or all tumor cells (bottom) in the tumor mice after treated with vehicle or PB-020. Mean ± SEM, N =
6 for each group. K) The docking model of PB-020 in the ligand-binding site 1 of apo IGF1R. The zoom-in view of PB-020 bound in the binding site 1
of IGF1R. L) The comparison of the docked binding modes of PPP and PB-020 in the ligand-binding site 1 of apo IGF1R. Comparing to PPP, PB-020 is
pushed out a little bit further to the entrance of the IGF1 binding pocket (marked as dark gray shade) because of two fluorine atoms. All oxygen atoms
are colored in red. *p < 0.05, **p < 0.01, ns, no significance.
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important target for glioma the treatment of some gliomas. This
notion is supported by a recent study that tumor OPCs existed
as the cancer stem cells in human GBMs and may function to
resist to therapy.[44] More work should be done to further stratify
GBMs to determine the suitable patients with the best prognosis
with IGF1R targeted therapy. It would be highly interesting to in-
vestigate whether those with glial tumors where the cells having
OPC identities constitute the majority of the tumor mass, such
as proneural subtype of GBM, oligodendrogliomas, and DIPGs,
would particularly benefit from IGF1R targeted therapy.
One interesting topic in the future is to identify the in vivo cel-
lular source of IGF1. Given the establishment of the importance
of IGF1R axis in gliomagenesis and TICs maintenance, at least
the ones related to OPCs, in the current study, interruption of
the communication from the ligand side can be a novel strategy
for IGF1R-based anti-glioma therapy. Indeed, a recent work sug-
gest that tumor associated microglia (TAM) have been reported
to be one source of IGF1.[16] Interestingly, subtype of neurons in
the brain and hepatocytes in liver also express IGF1.[45,46] Dissec-
tion the individual roles of these cellular sources in gliomagene-
sis and the self-renewal of glioma TICs are currently undergoing.
Clinical trials targeting IGF1R in patients with advanced solid
tumors have been described.[47–50] While conflicting results were
sometimes encountered, some patients exhibited profound re-
sponses to IGF1R inhibitor monotherapy, supporting the notion
that IGF1R-targeting is tumor and cellular/oncogenic context-
dependent. Given the poor ability of currently available IGF1R
inhibitors to penetrate the brain, clinical trials of IGF1R target-
ing in gliomas lag behind those focusing on other solid tumors.
Despite our studies on the mouse model suggesting a marginal,
if any, brain-penetration capacity of PPP, the lead molecule from
which PB-020 was developed (Figure 8), a recent and thus far the
only phase-I clinical trial shows that PPP was well tolerated and
demonstrated some ability to prolong survival of a small number
of GBM patients.[23]
One explanation for this discrepancy is that PPP may par-
tially inhibit gliomas by suppressing angiogenesis. In fact, our
scRNA-seq data revealed that endothelial cells in glioma strongly
expressed IGF1R, which could be the target of IGF1R antag-
onists. Supporting this speculation, Zamykal et al. reported
that IGF1R neutralizing antibody may inhibit the intracranial
growth of U87MG by targeting the growth of blood vessels.[21]
Therefore, clinical administration of BBB-penetrable IGF1R in-
hibitor is expected to have multiple anti-glioma effects, both cell-
autonomously and noncell autonomously. The gain of the BBB-
penetrating capacity and better pharmacokinetic profile position
PB-020 as a putative anti-glioma therapeutic agent, either alone
or in combination with other therapies. Comprehensive exam-
inations by using variable subtypes of human gliomas should
be further performed and additional modifications might be ex-
pected before moving PB-020 to clinical trials.
4. Experimental Section
Ethics: All animal procedures followed the animal care guidelines ap-
proved by the Institutional Animal Care and Use Committee of Zhejiang
University School of Medicine. All human glioma samples in this study
were received from patients with written informed consents; and the pro-
tocol was approved by the ethics committee of Zhejiang University School
of Medicine.
Antibodies and Key Reagents: Information for all antibodies and key
reagents can be found in Table S1, Supporting Information.
Mouse Models: Following strains were used to build up the genetic
mouse models in this study: NG2-CreER, p53KO, Rosa-tdTomato (Ai9,
stock no.007909, JAX), NF1flox, p53flox, IGF1Rflox (stock no.012251, JAX),
Nestin-CreER, TG11ML (stock no.022977, JAX), GT11ML (stock no.022976,
JAX), hGFAP-Cre (stock no. 004600, JAX), and NG2-Cre (stock no. 008533,
JAX).
Human Samples: The detailed information of human subjects refers
as to Table S2, Supporting Information. Fresh glioma tissues were directly
dissected from surgery and processed within 8 h.
Cell Lines: Glioma cell lines #1483 and #1877 were derived from the
CKO_NG2-CreER mouse model. Cell line #3841 was from the MADM-
hGFAP-Cre mouse model. #1920 cell line was from the CKO_NG2-
CreER_IGF1R (flox/flox) mouse model. #4612 cell line was derived from
glioma mouse model generated by PB transposon-based CRISPR-cas9 sys-
tem to knock out Trp53, Rb1, and Pten through neonatal electroporation.
Human GBM cell lines were established from freshly resected tumor tis-
sues of GBM patients during surgery. All human glioma cell lines (#H2,
#H5, #H63) used in this paper were cultured in complete media with EGF
and FGF. The MEF cells were derived from the mouse embryos with de-
sired genotypes at the age of Embryonic (E) day E13.5. The WT MEFs and
the Trp53−/−; NF1−/− MEF cell lines were established from the WT_NG2-
CreER and the CKO_NG2-CreER models, respectively. Trp53/NF1 mutant
OPCs were enriched from the neonatal (P8) CKO_NG2-Cre model by anti-
O4 immunopanning. The detailed procedures to preparation and mainte-
nance of cell lines are described in the Supporting Information.
Human Tissue Preparation and Histology: Fresh human glioma tissues
were divided into two parts. One part was directly immersed into 30%
formalin and subjected to formalin-fixation-paraffin-embedding prepara-
tion. The other part was transported to the laboratory in ice-cold DMEM
supplemented with 1% penicillin/streptomycin. This second part of tu-
mor tissue was further divided into three fractions: one was diced into
small chunks and gone through fixation and O.C.T. embedding as previ-
ously described[29]; the second fraction was snap-frozen in liquid nitrogen
for RNA-sequencing and qPCR; the third one was digested by papain into
single cells and used for primary culture or immunopanning.
Immunofluorescence Histological Analyses: All mouse frozen tissues
were cryosectioned into 20 µm thickness and refixed into ice-cold 2% PFA
at room temperature for 15 min. The protocol of immunostaining for hu-
man tissue sections refers to previous studies by the authors.[7,29] For hu-
man tissue sections, 0.3% Sudan Black B was used to quench the autoflu-
orescence.
Cell Culture: Mouse glioma cell lines were maintained in the mouse
glioma cell culture complete media, which contained neurobasal me-
dia, l-Glutamine, penicillin/streptomycin, sodium pyruvate, d-biotin, gen-
tamycin, trace element B, B27 minus VA. The cell lines were cultured
in T25 flasks precoated with poly-d-lysine. All human GBM cell lines
were maintained in the human GBM complete media, which contained
Neurobasal media, l-glutamine, penicillin/streptomycin, sodium pyru-
vate, d-biotin, gentamycin, trace elements B, B-27 minus VA, transferrin,
BSA, putrescine, progesterone, sodium selenite, insulin, and GFs as indi-
cated. DBTGR /KNS-81 were cultured in DMEM, supplemented with peni-
cillin/streptomycin and 10% FBS. U87MG was cultured in DMEM, supple-
mented with penicillin/streptomycin, 10% FBS, sodium pyruvate, MEM
nonessential amino acids solution. Culture media was half changed ev-
ery week and passaged as routine. MEF cell line was prepared from E13.5
embryos with proper genotype. The torso without head, arms, legs, and
viscera was minced and digested by TrypLE, and dissociated into single
cells before cultured and maintained in DMEM, supplemented with peni-
cillin/streptomycin and 10% FBS.
Immunopanning: The dissociated human GBM cells were briefly cul-
tured in the complete media (without GF) at 37 °C 5% CO2 for 12–14 h
before immunopanning. Overnight-cultured GBM cells were trypsinized
with prewarmed TypLE and washed with DPBS (w/o Ca2+ and Mg2+). The
cell palette was washed and resuspended into the panning buffer (DPBS
with Ca2+ and Mg2+, 0.02%BSA) and transferred to Goat Anti-Mouse
IgG (Jackson Immuno Research, #115-005-003)-coated plate at room
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temperature for 8 min. The supernatant was then transferred to the pre-
washed anti-CD140𝛼 antibody (BD Pharmingen, #556001) coated plate
and incubated at room temperature for 15 min. The enriched tumor
OPCs were collected from the plate by TrpLE. Immunopanning of mouse
neonatal OPCs were performed as previously described by using anti-
O4 antibody.[51] The cells were maintained in PDGFAA and FGF (20 ng
mL−1 each) until used.
Flow Cytometry Analysis and Cell Sorting: Dissociated cells were in-
cubated with desired antibodies for 30 min at room temperature fol-
lowed by FACS analysis or sorting on CytoFLEX LX or BD FACSAria
II and Beckman moflo Astrios EQ cell sorter .The antibodies used for
FACS are: PE-conjugated Mouse Anti-Human CD221 (BD, #555999),
Alexa FluorR 647-conjugated Mouse Anti-Human CD140𝛼 (BD, #562798),
APC-conjugated IGF1R (Abcam, #ab225298); APC-conjugated Mouse
PDGFR𝛼 (BD, #FAB1062A); PE-conjugated anti-human PDGFR𝛼 (BD,
#FAB1264P); APC-conjugated anti-Human PDGFR𝛼 (BD, #FAB1264A).
Tumor sphere Assay: 1000 or 3000 cells were seeded into each well of
the 96-well plate and cultured in 0.1 mL mouse glioma cell basal media,
which contained Neurobasal media, l-glutamine, penicillin/streptomycin,
and B27 minus insulin. Cells were cultured for 4–7 days before analyzed.
Four wells were repeated for each condition. For human cells, 3000 cells in
100 µL GBM basal media supplemented with GFs and/or inhibitors were
seeded in each well of the 96-well plate. Four wells for each condition.
Isolation and Culture of Mouse Adult NSCs: The lateral SVZ of the mice
(from 2 to 5mice) with desired genotypes was micro-dissected and sin-
gle cell suspension was prepared using the Neural Tissue Dissociation kit
with Papain (Miltenyi, #130-092-628). Dissociated cells were transferred in
Neurobasal A/B27 media supplemented with 1% l-glutamine, 2 mg mL−1
of heparin, 20 ng mL−1 of human FGF (Peprotech, #100-18-B) and 20 ng
mL−1 of human EGF (Peprotech, #AF-100-15). Cells were not used for
longer than 6 passages.
Differentiation of Adult Mouse NSCs: Adult neural stem cells (NSCs,
≈3000 cells) were seeded on PDL-coated 96 wells plate in differentiation
medium consisted of Neurobasal A/B27, 1% l-glutamine, heparin, FGF2,
PDGFAA, and 2%FBS for 9–11 days, 1/2 media with fresh growth factors
were regularly replaced every 3–4 days.
Co-IP Assay: Mouse tumor OPCs or HEK293FT cells transfected with
the plasmids were lysed with Cell lysis buffer for Western and IP (Beyotime,
#P0013) supplemented with protease inhibitor (Roche, #21287100) and
phosphatase inhibitor (Roche, #26920800). Lysates were precleared by
mouse IgG (Abmart, #B30010S) and Protein A/G PLUS-Agarose (Santa
cruz, #sc-2003). The beads were pelleted by centrifugation at 2500 rpm
for 5 min at 4 °C, and supernatant was used for IP experiments.
Western Blots: Tissues or cultured cells were lysed in the cold RIPA
buffer supplemented with the protease inhibitor cocktail and phosphatase
inhibitor cocktail tablets. Protein samples were then subjected to the SDS-
PAGE by electrophoresis and transferred onto polyvinylidene difluoride
membranes as routine procedure. WB bands were detected with sec-
ondary antibodies coupled to horseradish peroxidase by using chemilu-
minescence methods with the ECL detection kit.
Tamoxifen and BrdU administration: Tamoxifen citrate (TAM) was
orally administrated via gavage at a concentration of 200 mg kg−1 (pre-
pared in ddH2O) body weight for 5 days (1 dose per day) at P31–35 to
induce recombination. For repeated administration of TAM given in Fig-
ure 2I, TAM was intermittently given as a 15day-cycle until the mice showed
symptoms. BrdU was administered by intraperitoneal injection (i.p.) at a
concentration of 50 mg kg−1 (prepared in 1× PBS) body weight for 8 days
(1 dose per day). Mice were sacrificed 2 h after the last injection of BrdU.
Intracranial Grafting of Mouse and Human Glioma Cells: Mouse
(10 000 cells per mouse) or human glioma cells (100 000–300 000 cells per
mouse) were suspended into Neurobasal media as a density of 5 000 000
or 50 000 000 viable cells mL−1 and grafted into the brains of NOD-SCID
mice. After the surgery, the mice were monitored daily and sacrificed at the
onset of neurological symptoms, or based on the designed time points.
The coordinates of grafting (measured according to bregma) was 1 mm
anterior, 1 mm lateral, and 3.5 mm deep.
Synthesis of PB-020 [(5R,5aS,8aR,9R)-2,2-difluoro-9-hydroxy-5-(3,4,5-
tris(methoxy-d3)phenyl)-5,8,8a,9-tetrahydrofur′[3′,4′:6,7]naphtho[2,3-d]
[1,3]dioxol-6(5aH)-one-9-d]: The detailed method for compound syn-
thesis is provided in the Supporting Information. Briefly, to a stirred
solution of intermediate 1.6 (400 mg, 0.89 mmol, 1.0 eq.) in methanol
(10 mL), NaBD4 (37.5 mg, 0.89 mmol, 1.0 eq.) was added in portions,
and the resultant mixture was stirred for 4 h. The reaction was quenched
with water, and was concentrated to dryness. The obtained residue was
diluted with water, and extracted with EtOAc. The combined organic
phase was washed with brine, dried over MgSO4, and concentrated to
dryness. The obtained residue was recrystallized from PE/EtOAc to yield
compound PB-009 (140 mg, 35% yield) as white solid. Compound PB-019
was synthesized in a similar way as compound PB-009, using 3,4,5-tris
(trideuteriomethoxy) benzaldehyde as the starting material. Compound
PB-020 was prepared by chiral separation of compound PB-019 on chiral
column chromatography.
Evaluation for BBB Penetration: The mice were dosed by gavage with
50 mg kg−1 of PPP, PB-004, PB-016, or PB-020 dissolved in DMSO/corn oil
(1:9 v/v) solution. At predosing (0 h) and 1, 3, 6, 12, and 24 h post-dosing
time points, the blood samples (approximately 1 mL) were collected from
abdominal aorta, and the plasma samples were subsequently transferred
into centrifuge tubes by centrifuging for 5 min at 4000 rpm. The brain tis-
sues were collected and immediately frozen in liquid nitrogen. Approxi-
mately 0.3 g brain tissues were evenly divided into two parts. One part
was homogenized in acetonitrile for HPLC assay, and the other part was
homogenized in RIPA solution for immunoblotting. For HPLC-UV assay,
samples were subjected to the HPLC system (Hitachi Chromaster, Japan).
The tested compounds present in the plasma or brain samples were identi-
fied by matching the peaks of retention time for the reference compounds,
and their concentrations were determined by measuring the areas under
the peaks.
Single Cell Transcriptome Sequencing: Single cells were processed
through the 10× Chromium 5’ (for the primary tumor sample) or 3’ (for
all cell lines) Single Cell Platform using the Chromium Single Cell 5’ or 3’
Reagent Kits v3, Gel Bead and Chip Kits (10× Genomics, Pleasanton, CA),
following the manufacturer’s protocol (Illumina). In this study, tdTomato
gene inherent was added in the mouse model gene list to obtain the final
matrics by modifying the reference genome. The matrix was separated by
the cell type judgment result obtained by the cellranger. Cells with high
quality were selected with the following criteria: 1) Genes detected in < 3
cells were removed; 2) cells with unique molecular identified (UMI) ≤ 150
or ≥ 4500 were removed. 3) Cells with ≥ 20% mitochondrial counts were
removed. Normalization was performed using Seurat.[52] R package Seu-
rat was used for unsupervised clustering. Monocle was used to construct
single-cell pseudo-time trajectories.[53]
Bulk Transcriptome Sequencing: Human GBM tissues and four pairs
of panned and supernatant GBM fractions were analyzed by RNA-Seq
(Table S5, Supporting Information). The sequencing libraries of the four
pairs of panned and supernatant human glioma cells were built based on
Ovation Universal RNA-Seq System and the seven human GBM tissues
were prepared by the Truseq Stranded mRNA LT Kit. The libraries were se-
quenced on Illumina Hiseq platforms by Shanghai Personal Biotechnology
Co., Ltd. The Genepattern online tool (https://genepattern.broadinstitute.
org/) was used to calculate ssGSEA. The subtractive ssGSEA enrichment
scores between panned and supernatant fractions from each sample were
presented as the difference of the ssGSEA scores for the four subtypes.
GO-Term Analysis: Differential expression genes (DEGs, log2-fold
change > 1, p < 0.05) were screened by DESeq in each pair of immune-
panned cells and supernatant cells. Those DEGs were then used for the
GO Enrichment Analysis online (http://geneontology.org/) to generate re-
lated enriched pathway.
Imaging Collection and Processing: All confocal images were collected
by an Olympus FV-3000 inverted confocal microscopy and analyzed with
Olympus Fluoview 1000 software. All sphere culture images in cell culture
were collected using an Olympus CKX53 microscope and processed by
Image J.
Statistics and Reproducibility: Survival curves were analyzed and pre-
sented as the Kaplan–Meier survival curves. The comparison between
curves were performed by the log rank test. Student’s t-test was used to de-
termine the statistical significance of all quantification. Values of p < 0.05
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were considered as significant. Statistical analysis was performed using
GraphPad Prism 5. Data were presented as mean ± SEM. Each in vitro
experiment has been independently repeated at least twice. No statistical
methods were used to predetermine sample sizes, but the sample sizes
herein were similar to those reported in previous publications.[5,54,55] Data
distribution was assumed to be normal, but this was not formally tested.
Randomization of animal studies was used in the data analysis. Data col-
lection and analysis were not performed in a blinded manner to the con-
ditions of the experiments. Detailed quantification schemes in this paper
can be found in the Supporting Information.
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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